A 10mg vial from an unverified supplier typically sits around AUD $120 to AUD $200
Compared with older single pathway options, the goal is broader metabolic support that can translate into stronger and more consistent results for some patients
Notably, KFFs 2025 Medicaid budget survey found 16 state Medicaid programs covered GLP-1s for obesity treatment as of October 2025
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: analysis from the CVD-REAL 2 study
If ongoing trials continue to deliver positive results, triple agonist therapies for diabetes may represent the next major evolution in treating obesity, type 2 diabetes, and related metabolic diseases
As with any new medicine, phase 3 trials and ongoing pharmacovigilance will define the real-world safety picture